Lenalidomida Sandoz (Lenalidomide)

Lenalidomide is employed in the treatment of hematologic malignancies and related disorders.

• Multiple Myeloma: improves progression‑free survival and overall response in adult patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission in eligible adults.
• Mantle Cell Lymphoma: provides disease control in patients with relapsed or refractory mantle‑cell lymphoma.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, triggering ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of the immune micro‑environment, inhibition of angiogenesis, and direct anti‑proliferative and pro‑apoptotic effects on malignant plasma cells and other hematologic tumor cells.

Lenalidomide may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count increasing infection risk.
• Thrombocytopenia: reduced platelet levels leading to bleeding tendencies.
• Anemia: lowered red blood cell count causing fatigue.
• Fatigue: general tiredness and weakness.
• Nausea: upset stomach and possible vomiting.
• Diarrhea: loose stools and abdominal discomfort.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: liver enzyme elevations or liver injury.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Interstitial lung disease: inflammation of lung tissue leading to breathing difficulties.

When prescribing Lenalidomida Sandoz, clinicians should consider several safety measures and monitoring requirements.

• Pregnancy contraindication: drug is teratogenic (Category X) and must not be used during pregnancy.
• Thrombosis risk: assess for clotting risk and consider prophylactic anticoagulation.
• Hematologic monitoring: regular CBCs to detect neutropenia, thrombocytopenia, and anemia.
• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic impairment: monitor liver function tests and adjust therapy as needed.
• Store below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants: increased bleeding risk when combined.
• CYP inducers (e.g., rifampin): may lower lenalidomide exposure.
• Strong immunosuppressants: may diminish therapeutic effect.
• Live vaccines: heightened risk of infection due to immunosuppression.
• Thalidomide: additive teratogenic potential; concurrent use is contraindicated.

Moderate Interactions (Monitor Closely)

• NSAIDs: may exacerbate renal toxicity.
• Digoxin: possible increase in serum levels.
• P‑gp inhibitors (e.g., verapamil): may raise lenalidomide concentrations.
• Non‑live vaccines: efficacy could be reduced.
• Hormonal contraceptives: potential decrease in effectiveness, requiring additional contraceptive measures.